Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity in Metastatic ccRCC
November 7th 2020In patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy, the combination of lenvatinib and pembrolizumab achieved antitumor responses, according to results from a phase 2 trial.
Read More
Cabozantinib Leading the Emerging Therapies in Advanced RCC
November 6th 2020In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed key results from the CheckMate-9ER trial in advanced renal cell carcinoma, as well as ongoing trials with the potential to move the landscape further along.
Read More
Lenvatinib Combo Shows Promising Findings in Phase 2 Study of Non-Clear Cell Renal Cell Carcinoma
November 6th 2020Lenvatinib plus everolimus demonstrated anti-tumor activity as treatment of patients with advanced non-clear cell renal cell carcinoma in the frontline setting, according to findings from a phase 2 clinical trial.
Read More
More Funding of Cancer Research Crucial for Continued Advancements
November 6th 2020Over the years, cancer treatments that have improved patients outcomes have come out of clinical trial research. These studies have greatly contributed to the decline in cancer mortality in the United States since 1975, as well as the global cancer burden and mortality rate. During a presentation for the 38th Annual Chemotherapy Foundation Symposium (CFS), Clifford A. Hudis, MD, explained the need for monetary investment in research initiatives.
Read More
Selecting I/O or Targeted Therapy as Adjuvant Treatment of BRAF-Mutant Melanoma
November 5th 2020During a virtual presentation for the 38th Annual Chemotherapy Foundation Symposium, Janice M. Mehnert, MD explained the science behind selecting the optimal adjuvant therapy for patients with BRAF-mutant melanoma. The options Mehnert weighed were immunotherapy and BRAF-targeted therapy.
Read More
PARP Inhibitors Make Advances to mCRPC Treatment Paradigm
November 5th 2020In the treatment landscape of metastatic castration resistant prostate cancer, the introduction of PARP inhibitors as a therapeutic option has led to progress, explained Maha Hussain, MD, in a presentation during the 38th Annual Chemotherapy Foundation Symposium.
Read More
Expert Reviews Sequencing Strategies for Explosion of New CLL Treatment Options
November 4th 2020While the treatment landscape for chronic lymphocytic leukemia has expanded with an explosion of new therapeutic options, physicians are plagued with questions about sequencing therapies for those who progress following therapy in the first-line setting, and little data exists to guide optimal therapy selection, according to Anthony Mato, MD.
Read More
In Low-Grade Follicular Lymphoma, Expert Weighs Frontline Options
November 4th 2020A general framework can be utilized to guide treatment decision in patients with follicular lymphoma, according to John P. Leonard, MD. During a presentation for the 38th Annual Chemotherapy Foundation Symposium, Leonard also explained that bulk of disease, comorbidities, and toxicity, among others are all factors that impact treatment decisions.
Read More
Novel Bispecific Monoclonal Antibody Demonstrates Preclinical Promise Against STEAP1 Target in mCRPC
October 23rd 2020In a presentation during the 27th Annual Prostate Cancer Foundation Scientific Retreat, W. Kevin Kelly, DO, explained the potential of this novel agent and its development progress.
Read More
AR/AKT Combination Bests AR Blockade in mCRPC with PTEN Loss
October 23rd 2020The combination of ipatasertib and abiraterone acetate achieved a significantly superior radiographic progression-free survival and demonstrated anti-tumor activity compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer with PTEN loss, according to results from the phase 3 IPATential150 clinical trial.
Read More
PSMA-Targeted Therapies in Clinical Development Show Promise for Prostate Cancer
October 23rd 2020Naomi Haas, MD, discusses several areas of interest for the treatment of patients with prostate cancer that are utilizing PSMA, including bispecific T-cell engager antibodies, chimeric antigen receptor T cells, and the lutetium studies.
Watch
BXCL701 Split Dosing Improves Tolerability in Metastatic Castration-Resistant Prostate Cancer
October 22nd 2020Split-dosing of BXCL701 at 0.6 mg per day is a supported dosing strategy for the agent in combination with pembrolizumab as treatment of patients with metastatic castration-resistant prostate cancer, according to phase 1b/2 study results.
Read More
PLK1 Inhibitor, Abiraterone Combo Shows Preliminary Efficacy and Safety in mCRPC
October 22nd 2020In a phase 2 trial, onvansertib, a polo-like kinase 1 inhibitor, combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have early abiraterone resistance, demonstrated a decent safety profile across 3 dosing schedules and efficacy in the evaluable arms.
Read More
Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients
October 11th 2020During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.
Read More
Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis
October 11th 2020During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.
Read More
Expert Reviews New Diagnostic and Staging Criteria in Multiple Myeloma
October 11th 2020In an interview with Targeted Oncology, Jens Hillengass, MD, shared his insights on the latest edition of the diagnostic and staging criteria for multiple myeloma that have become standard now for the management of these patients.
Read More
Hot Topics of Discussion in the Management of Multiple Myeloma
October 11th 2020Jens Hillengass, MD, discusses the key takeaways from his presentation at the 2020 National Comprehensive Cancer Network Virtual Congress: Hematologic Malignancies, in which he shared his insights on the diagnostic and staging criteria in multiple myeloma.
Watch
Management of Early Stage Hodgkin Lymphoma Requires “Balancing” Individual Risk
October 10th 2020When choosing therapy for patients with early stage Hodgkin lymphoma, considering risk scoring systems and Deauville criteria for PET-adapted therapy are key conditions for optimizing survival rates, according to Ranjana H. Advani, MD.
Read More
Limited Activity Shown With Durvalumab/Tremelimumab in Advanced NETs Subtypes
September 22nd 2020Results from the DUNE trial of durvalumab added to tremelimumab in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins showed limited activity, according to a presentation held during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma
September 21st 2020Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.
Read More
Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
September 21st 2020Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.
Watch
Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes
September 21st 2020Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Atezolizumab Plus Bevacizumab and Chemotherapy Misses PFS End Point in Ovarian Cancer Trial
September 21st 2020In patients with newly diagnosed stage III/IV ovarian cancer, adding atezolizumab to a backbone combination of bevacizumab and chemotherapy did not improve progression-free survival, missing the primary end point of the phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial presented during the virtual 2020 European Society of Medical Oncology Congress.
Read More